PubMed · 1979 · 35 citations · 0 references
MedicineMedicinal ChemistryPharmacologyCancer PharmacologyChemotherapyOrganometallic ChemistryAntineoplastic Drug ClassesMalignant NeoplasmsAnticancer ActivityAntineoplastic Drug AdministrationAntineoplastic Drug TherapyCancer Cell Proliferation InhibitionMetallocene Synthesis
The antitumor activity of molybdocene dichloride is tested against Ehrlich ascites tumor in CF1 mice. The application of 75 of 100 mg/kg 24 h after transplantation achieves 100% tumor inhibition until day 30. Following the d0 and d1 metallocene dichlorides of titanium and vanadium, molybdocene dichloride is the first analogous d2 system revealing similar antineoplastic properties.